Endocrinology, radiobiology and cancer endocrinology - Patents
Groups
- Endocrine-Metabolic Clinical Biochemistry
- Translational vascular physiopathology, diabetic retinopathy and clinical pedagogy: Brizzi/Bruno Lab
Inventors
MF Brizzi, E. Ghigo
Patent Title
Use of unacylated ghrelin, fragments and analogs thereof as antioxidant
Filing date
6/5/2020
Application number
EP3010529B1
Link
https://patents.google.com/patent/EP3010529B1/en
Abstract
According to one aspect, the present invention relates to a fragment of unacylated ghrelin and/or pharmaceutically acceptable salts thereof wherein the fragment consists of amino acid sequence SEQ ID NO: 6 and/or pharmaceutically acceptable salts thereof, for its use in protecting a subject against reperfusion injury; particularly when the subject suffers from ischemia, or suffers from a stroke, or for protecting a subject from reperfusion injury following organ transplantation or for preventing ischemia-reperfusion injury in the subject. Particularly, the UAG fragment for the use of the invention modulates cellular levels of superoxide-dismutase-2 (SOD-2). The modulation of cellular levels of SOD-2 includes increasing cellular levels or expression of SOD-2.
Groups
- Biochimica Clinica Endocrino-Metabolica
- Fisiopatologia vascolare traslazionale, retinopatia diabetica e pedagogia clinica: Brizzi/Bruno Lab
Inventors
G. Muccioli, E. Ghigo, MF Brizzi
Patent Title
Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
Filing date
13/03/2018
Application number
CA2723270C
Link
https://pubchem.ncbi.nlm.nih.gov/patent/EP-2310041-A2
Abstract
The present invention relates to a method for treating a cardiovascular disease, for increasing the number of circulating angiogenic cells (CAC) and/or improving the function of CAC and a method for improving vascular remodeling and/or neovascularisation. The method comprises administering to the subject a therapeutically effective amount of unacylated ghrelin or a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 1 or a fragment or analog thereof having the biological activity of SEQ ID NO: 1; and to pharmaceutical compositions comprising unacylated ghrelin or a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 1 or a fragment or analog thereof having the biological activity of SEQ ID NO: 1.
Groups
- Endocrine-Metabolic Clinical Biochemistry
- Translational vascular physiopathology, diabetic retinopathy and clinical pedagogy: Brizzi/Bruno Lab
Inventors
E. Ghigo, G. Muccioli, MF Brizzi
Patent title
Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
Filing date
06/03/2014
Application number
AU2009256558B2
Groups
- Endocrine-Metabolic Clinical Biochemistry
- Translational vascular physiopathology, diabetic retinopathy and clinical pedagogy: Brizzi/Bruno Lab
Inventors
MF Brizzi, G. Muccioli, E. Ghigo
Patent title
Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
Filing date
13/02/2013
Application number
EP2310041B1
Link
https://patents.google.com/patent/EP2310041B1/de
Group
Inventors
Ezio Ghigo, Aart Jan Van Der Lely, Riccarda Granata
Patent title
Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
Filing date
2010
Application number
AA61K3802FI USPC
Link
https://iris.unito.it/handle/2318/68703
Abstract
An isolated polypeptide comprising any amino acid fragment of unacylated ghrelin or any analog thereof, wherein the polypeptide has an activity selected from the group consisting of a) decreasing blood glucose levels; b) increasing insulin secretion an/or sensitivity; c) binding to insulin-secreting cells; and d) promoting survival of insulin-secreting cells. As well as the use of the polypeptide in the treatment of a disorder associated with impaired glucose metabolism.